Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GnRH agonists vs antagonists.

B C Tarlatzis1, E M Kolibianakis

  • 1Unit for Human Reproduction, 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece. Tarlatzis@hol.gr

Best Practice & Research. Clinical Obstetrics & Gynaecology
|October 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Follicular flushing increases the number of oocytes retrieved: a randomized controlled trial.

Human reproduction (Oxford, England)·2023
Same author

Patient burden and healthcare resource utilization of regimens for ovarian stimulation.

Reproductive biomedicine online·2022
Same author

Ovarian tissue cryopreservation and transplantation to delay menopause: facts and fiction.

Maturitas·2020
Same author

Is pretreatment with GnRH agonist necessary for endometrial preparation for frozen embryo transfer cycles in women with polycystic ovary syndrome?

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

A decision-making algorithm for performing or cancelling embryo transfer in patients at high risk for ovarian hyperstimulation syndrome after triggering final oocyte maturation with hCG.

Human reproduction open·2020
Same author

Is the probability of pregnancy after ovarian stimulation for IVF associated with serum estradiol levels on the day of triggering final oocyte maturation with hCG? A systematic review and meta-analysis.

Journal of assisted reproduction and genetics·2020
Same journal

A risk-based classification of late-onset fetal growth disorders according to intrapartum fetal compromise.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

The Cardiac-Fetal-Placental Unit: links between umbilical venous flow and maternal hemodynamics in fetal growth restriction.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Psychosocial interventions for women who are pregnant following a previous reproductive loss: A scoping review.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Controversies in fetal therapy.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Alloimmunisation in pregnancy: current management and future perspectives.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Consensus in prenatal management of Hemolytic disease of the fetus and newborn.

Best practice & research. Clinical obstetrics & gynaecology·2026
See all related articles

GnRH antagonists offer a more patient-friendly ovarian stimulation for IVF compared to agonists, with similar live birth rates. Antagonists reduce FSH stimulation duration and hospital admissions for OHSS.

Area of Science:

  • Reproductive Endocrinology
  • In-Vitro Fertilization (IVF)

Background:

  • Gonadotropin-releasing hormone (GnRH) agonists are used in IVF to prevent premature luteinizing hormone (LH) surges.
  • Agonists have disadvantages like hypoestrogenaemia and prolonged downregulation, despite improving pregnancy rates.

Purpose of the Study:

  • To compare the efficacy and safety of GnRH antagonists versus agonists in ovarian stimulation for IVF.
  • To evaluate the impact on stimulation duration, OHSS incidence, and live birth rates.

Main Methods:

  • Comparative analysis of studies evaluating GnRH agonists and antagonists in IVF protocols.
  • Assessment of key outcomes including duration of follicle-stimulating hormone (FSH) stimulation and hospital admissions.

Main Results:

Related Experiment Videos

  • GnRH antagonists provide immediate action and shorter administration periods, offering greater flexibility.
  • Antagonist use is linked to reduced FSH stimulation duration and lower rates of ovarian hyperstimulation syndrome (OHSS).
  • Live birth probability remains consistent regardless of whether agonists or antagonists are used.

Conclusions:

  • GnRH antagonists represent a more convenient and potentially safer alternative for ovarian stimulation in IVF.
  • The choice between GnRH agonists and antagonists does not appear to affect the ultimate success rate in terms of live births.